Abstract: As part of a programme aimed at identifying rational new triple drug combinations for treatment of malaria, tuberculosis and toxoplasmosis, we have selected quinolones as one component, given that selected examples exhibit exceptionally good activities against the causative pathogens of the foregoing diseases. The quinolone decoquinate (DQ), an old and inexpensive coccidiostat, displays anti-malarial activity in vitro against Plasmodium falciparum (Pf). However, because of its exceedingly poor solubility in water or organic solvents, development of DQ as a drug is problematical. We have therefore converted DQ in straightforward fashion into tractable new derivatives that display good activities in vitro against chloroquine-sensitive NF54 and multidrug-resistant K1 and W2 Pf, and relatively low toxicities against human fibroblast cells. The most active compound, the N-acetyl derivative 30, is 5-fold more active than DQ against NF54 and K1 and equipotent with DQ against W2. It possesses an activity profile against all strains comparable with that of the artemisinin derivative artesunate. Overall, this compound and the other accessible and active derivatives serve as an attractive template for development of new and economic lead quinolones. which renders it substantially cheaper than the other 4(1H)-quinolones proposed for further development as antimalarial drugs.
. Amides obtained from direct aminolysis of decoquinate 1 with primary and secondary amines in chloroform according to method a, Scheme 1; reaction time (h), overall yields given.
For the ester aminolysis (step a, Scheme 1), DQ is acidic with a pKa of 9.81,21 and thus a basic amine nucleophile under standard aminolysis conditions 25 is likely to undergo competitive equilibrating proton transfer with H-1 of the 4(1H)-quinolone (cf. Figure 2 below). Whilst this problem may be countered by the use of Lewis acidic reagents, 26 base-catalyzed aminolysis with an amine and 1,8-diazabicyclo [5.4 .0]undec-7-ene (DBU) 27 attracts because of its economy. Although the reactions may be conducted with the neat reactants and reagents, the most expeditious involved the heating of DQ and excess of primary or secondary amine with DBU in a solvent. We use chloroform here because of lack of solubility of DQ in other solvents, although it is emphasized that our initial concern is to obtain the new derivatives in the first place and then to optimize preparation for hit compounds using industrially acceptable solvents. Amides 2-21 (Fig 1) were obtained in good yields. Characterization data for the compounds are given in the Supplementary Material.
For functionalization at N-1 according to route b, Scheme 1, the decoquinate morpholino amide 2 was selected.
Although the pKa of amide 2 with respect to deprotonation at N-1 is unknown, it is likely this will be efficiently deprotonated by DBU in aprotic solvents to give the conjugate base 2 -that as an ambident anion may react through N-1 or O-4. In the event, the reactions with various acyl and sulfonyl chlorides, and alkyl halide proceeded smoothly through N-1 to give the products 22-29 in good yields ( Figure 2 ). Whereas the IR spectrum of compound 2 shows an absorption at 3162 cm -1 due to the N-H stretching vibration in the quinolone nucleus, the peak is absent in derivatives 22-29, and a signal due to C-4 bearing an oxo group is evident at ca. 170 ppm in the 13 C NMR spectra. Decoquinate 1 was also functionalized at N-1 according to Scheme 1 route c to give the N-substituted decoquinate derivatives 30-35 in good yields ( Figure 3 ). Data for derivatives 30, 31 and 33 appear in the Supplementary Material. As above, reaction through N-1 occurs in all cases. This is evident from the 13 C NMR spectra, which contain signals due to C-4 bearing an oxo group at ca. 170 ppm and the ester carbonyl at 160-165 ppm. In summary, decoquinate 1 is converted readily via aminolysis of the ethyl ester with primary and secondary amines in the presence of DBU in chloroform under reflux into the corresponding secondary and tertiary amides. Decoquinate 1 and the morpholino amide 2 under the foregoing conditions react with acyl and sulfonyl halides and alkyl halides through N-1 to provide new N-substituted derivatives in good yields.
Antimalarial activities: Decoquinate and the new derivatives were screened in vitro for antimalarial activity with the SYBR Green I-based fluorescence assay 28 against Pf NF54 asexual blood stage parasites to determine the % inhibition of proliferation at initial compound concentrations of 1 and 5 μM ( Figure S1 , Supplementary Material). Compounds showing the highest activity (>50% inhibition at 5 μM and >70% inhibition at 1 μM) were submitted to a second dual point assay at 100 nM and 500 nM ( Figure S2 , Supplementary Material). Compounds showing near complete inhibition of parasite proliferation were carried forward for IC 50 determination against chloroquine (CQ)-sensitive Pf NF54 and multidrug resistant K1 and W2. CQ, the artemisinins artemether and artesunate, and decoquinate 1 were used as controls. Cytotoxicity of the compounds was also evaluated with the sulforhodamine B (SRB) assay on the WI-38 cell line 29 using emetine as reference standard. IC 50 values are summarized in Table 1 . Of all compounds, only five, namely the decoquinate amides 3 and 6 ( Fig. 1 ) and the N-substituted decoquinate derivatives 30, 31 and 33 (Fig. 3) showed near complete inhibition at 1 and 5 M regardless of the parasite strain (Fig. S2, Supplementary Material (Fig. 3) on the other hand is equipotent with the two clinically used artemisinins against all strains, and is 5-fold more potent than DQ against Pf NF54 and K1, whilst being equipotent with DQ against W2. In general according to the resistance indices (Table 1) , the other compounds are less active against K1 with respect to drug sensitive NF54, and essentially equipotent with DQ against W2.
Although derivative 30 shows slight differences in activities between the three parasite strains, the selectivity indices indicate it is more selective than DQ in its antimalarial activity. Thus the balance between strain susceptibility, efficacy and safety favors derivative 30 over the parent decoquinate. It is to be noted that with the exception of compound 3, cLogP values indicate that all compounds are less lipophilic than decoquinate, and were able to be screened by preparing solutions in DMSO. To conclude, the derivative 30 that has an in vitro activity profile comparable to that of artesunate coupled with a favorable incipient toxicity profile, and others of Table 1 represent easily accessible and economic hit compounds to guide the preparation of new and potent derivatives. As foreshadowed in the introduction, activities of these and related compounds against
Mycobacterium tuberculosis and Toxoplasma gondii have also been recorded, and will be reported elsewhere.
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General procedures
The amines, acyl, sulfonyl, carbamoyl and alkyl halides in this study were purchased from either Sigma Aldrich or AKSci and were used as supplied. NMR spectra were A full scan, ranging between 50-1500 m/z, was generated at a capillary voltage of 4500 V, end plate offset voltage of -500 V, and a collision cell RF voltage of 100 V.
Infrared (IR) spectra were recorded on a Bruker Alpha-P FTIR instrument. Melting points (mp) were determined with a Büchi melting point B-545 instrument and were uncorrected. Thin layer chromatography (TLC) was performed using silica gel plates (60F 254 ) (Merck) and components were visualized by ultraviolet light (254 nm). Silica gel 230-400 (particle size 40-63 μm) mesh was used for column chromatography.
Calculated LogP (cLogP) values were generated using ACD/ChemSketch version 14.02.
Syntheses
(a) To a 100 mL two neck flask containing decoquinate 1 (1 g, 2.34 mmol) and DBU (320 µL, 0.33 g, 2.1 mmol, 0.9 eq.) in chloroform (25 mL) was added the primary or secondary amine (5 eq.). The resulting mixture was stirred under reflux for 24-72 h. Progress of the reactions was monitored by tlc. Upon completion, the reaction mixture was concentrated in vacuo. The concentrated residue was taken into chloroform (20 mL) and washed with distilled water (4 x 20 mL). The organic layer was dried (Na 2 SO 4 ), filtered and the filtrate was evaporated to dryness to leave the crude product, which was subjected to flash column chromatography on silica gel. The product was eluted with a mixture of dichloromethane/methanol (10:1, v/v).
The product was recrystallized from ethyl acetate and air dried. The amide derivatives 2-21 were thereby obtained in good yields using this procedure. Data for derivatives 2, 3 and 6 are given below. DQ and key derivatives in this study have the general structure below. 
Compd
6-Decoxy-7-ethoxy-N-(4-fluorobenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide 3
White powder; yield: 80%, 0.82 g; m. 
6-Decoxy-7-ethoxy-N-[2-(2-hydroxyethoxy)ethyl]-4-oxo-1,4-dihydroquinoline-3-carboxamide 6
White powder; yield: 68%, 0.68 g; m. haematocrit, 1% parasitaemia) were treated with the DQ derivatives series.
1-Acetyl-6-decoxy-7-ethoxy-3-(morpholin-4-ylcarbonyl) quinolin-4(1H)-one 24
Ethyl-1-acetyl-6-decoxy-7-ethoxy-4-oxo-1,4-dihydroquinoline-3-carboxylate 30
The controls for this assay included chloroquine disulphate (1 μM, as positive control) and complete RPMI media (as negative control) and grown for 96 h at 37 °C under the 90% N 2 , 5% O 2 , and 5% CO 2 gas mixture in 96-well plates.
At the end of the 96 h growth period, equal volumes (100 μL each) of the P.
falciparum parasite cultures were combined with SYBR Green I lysis buffer (0.2 μL/mL 10 000 x SYBR Green I, Invitrogen; 20 mM Tris, pH 7.5; 5 mM EDTA; 0.008% (w/v) saponin; 0.08% (v/v) Triton X-100).
The samples were incubated at 37 °C for 1h after which the fluorescence was measured using a Fluoroskan Ascent FL microplate fluorometer (Thermo Scientific, excitation at 485 nm and emission at 538 nm). The 'background' fluorescence (i.e.
that measured in the samples derived from chloroquine-treated iRBC samples in which parasite proliferation was completely inhibited) was subtracted from the total fluorescence measured for each sample to provide a measure of parasite proliferation.
Data obtained were analysed in Excel 2010 and sigmoidal dose-response curves were plotted using GraphPad 6.0.
Decoquinate 1 and the derivatives were screened at 5 μM and 1 μM against the NF54 strain of asexual P. falciparum parasites to determine their % inhibition.
Compounds showing near complete inhibition at 5 μM and 1 μM ( Figure S1 ), were further screened at 500 and 100 nM against NF54 parasites ( Figure S2 ).
Compounds were weighed (1 mg) and dissolved in 100% DMSO and made up to a 10 mM stock and stored at -20°C. Some compounds, however, did not completely dissolve (2, 8, 12, 14, 22, 31, 32, 33, 34 and 35) despite being incubated at 37 °C for >1h. These were dissolved at lower stock concentrations (<5 mM) and treated with 1xPBS. Therefore, prior to assay these compounds were vortexed thoroughly and the suspensions were immediately used to make up the working solutions in complete RMPI-1640 media.
Solutions/suspensions of compounds were thawed at room temperature (~1 h) prior to an assay to prepare working solutions. The final starting concentrations (5, 1 μM and 500, 100 nM) were prepared in complete RPMI-1640 media and aliquoted in triplicate into a 96-well plate. The %DMSO in the starting concentration was 0.05% for the 5 μM, 0.000125% for the 1 μM, 0.05% for the 500 nM and 0.00000125% for the 100 nM drug concentrations; these concentrations were below the parasite inhibition threshold as previously determined in our laboratory. Compounds were incubated at 5 μM and 1 μM against asexual NF54 P. falciparum parasites. Several compounds showed near complete inhibition of parasite proliferation as determined with the SYBR Green I fluorescence based assay following incubation at 37 ºC for 96 h with decoquinate 1 as control. Data analysis were performed in triplicate for n = 3 independent biological repeats with GraphPad 6.0; the average % inhibition is shown and error bars indicate SEM. The most active compounds at 5 μM and 1 μM were incubated at 500 nM and 100 nM against asexual NF54 P. falciparum parasites. Eight compounds showed near complete inhibition of parasite proliferation as determined with the SYBR Green I fluorescence based assay following incubation at 37 ºC for 96 h. Data analysis were performed in triplicate for n=3 independent biological repeats with GraphPad 6.0; the average % inhibition is shown and error bars indicate SEM.
In vitro cytotoxicity
The WI-38 cell line (normal human fetal lung fibroblast) from ECACC was maintained as a monolayer cell culture at 37 °C, 5% CO 2 , 95% air and 100% relative humidity in EMEM containing 10% fetal bovine serum, 2 mM L-glutamine and 50 µg/mL gentamicin. For this screening experiment, the cells (21 -50 passages) were inoculated in 96-well microtiter plates at plating densities of 10 000 cells/well and incubated for 24 hours. After 24 hours, the cells were treated with the experimental drugs; which had previously been dissolved in DMSO and diluted in medium to produce five concentrations. Neat cells served as the control. The blank contained complete medium without cells. Parthenolide was used as a standard. The plates were incubated for 48 hours after addition of the compounds. Viable cells were fixed to the bottom of each well with cold 50% trichloroacetic acid, washed, dried and dyed by SRB. Unbound dye was removed and protein bound dye was extracted with 10 mM Tris base for optical density determination at a wavelength of 540 nm using a multiwell spectrophotometer. Data analysis was performed using GraphPad Prism software. 50% of cell growth inhibition (IC 50 ) was determined by non-linear regression.
